San Diego, CA, United States of America

Praopim Limsakul

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: University of California. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Praopim Limsakul. Retrieved from https://idiyas.com/inventor/praopim-limsakul

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Praopim Limsakul: Innovator in Genetic Engineering

Introduction

Praopim Limsakul is a notable inventor based in San Diego, California. He has made significant contributions to the field of genetic engineering, particularly in the development of immune effector cells.

Latest Patents

Limsakul holds a patent for "Genetically Engineered Immune Effector Cells Comprising R-Phycoerythrin-Targeting Receptor Conjugated Chimeric Antigen Receptor." This innovative work showcases his expertise in creating advanced therapeutic solutions.

Career Highlights

Limsakul is affiliated with the University of California, where he continues to push the boundaries of research in immunology and genetic engineering. His work has the potential to impact various medical applications.

Collaborations

He has collaborated with esteemed colleagues such as Yingxiao Wang and Yiqian Wu, contributing to a dynamic research environment that fosters innovation.

Conclusion

Praopim Limsakul's contributions to genetic engineering exemplify the spirit of innovation in the scientific community. His work not only advances the field but also holds promise for future medical breakthroughs.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…